Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma
نویسندگان
چکیده
منابع مشابه
Hair repigmentation associated with the use of brentuximab
cGVHD: chronic graft versus host disease IL: interleukin TNF: tumor necrosis factor INTRODUCTION Brentuximab vedotin is an antibody-drug conjugate that is approved by the US Food and Drug Administration to treat refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Numerous clinical trials are currently evaluating the efficacy of brentuximab for other conditions, including T-...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملthe use of appropriate madm model for ranking the vendors of mci equipments using fuzzy approach
abstract nowadays, the science of decision making has been paid to more attention due to the complexity of the problems of suppliers selection. as known, one of the efficient tools in economic and human resources development is the extension of communication networks in developing countries. so, the proper selection of suppliers of tc equipments is of concern very much. in this study, a ...
15 صفحه اولThalidomide for treatment of multiple myeloma: 10 years later.
Thalidomide, bortezomib, and lenalidomide have recently changed the treatment paradigm of myeloma. In young, newly diagnosed patients, the combination of thalidomide and dexamethasone has been widely used as induction treatment before autologous stem cell transplantation (ASCT). In 2 randomized studies, consolidation or maintenance with low-dose thalidomide has extended both progression-free an...
متن کاملRecent Advances of Thalidomide in the Treatment of Multiple Myeloma
1 st International Lymphoma Leukemia Myeloma (LLM) Congress Multiple Myeloma (MM) is a chemoresistant malignancy and for decades, the only active drugs were alkylating agents and high-dose corticosteroids. The introduction of novel agents (Thalidomide, Bortezomib and Lenalidomide) is changing the management of MM patients both for frontline therapy and at relapse. These agents have a different ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Case Reports
سال: 2016
ISSN: 1757-790X
DOI: 10.1136/bcr-2016-215521